General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0SBFOG
ADC Name
Anti-FGFR2/4 mAb-12422 SPDB-DM4
Synonyms
Anti-FGFR2/4-mAb-12422-SPDB-DM4
   Click to Show/Hide
Organization
Novartis AG
Drug Status
Investigative
Indication
In total 3 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Colorectal cancer [ICD11:2B91]
Investigative
Gastric cancer [ICD11:2B72]
Investigative
Drug-to-Antibody Ratio
3.6
Antibody Name
Anti-FGFR2/4 mAb 12422
 Antibody Info 
Antigen Name
Fibroblast growth factor receptor 2 (FGFR2); Fibroblast growth factor receptor 4 (FGFR4)
 Antigen Info 
Payload Name
Mertansine DM4
 Payload Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
 Linker Info 
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.07
nM
CVCL_0076
Gastric adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.07 nM Positive FGFR2 expression (FGFR2+++/++)
Method Description
Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.

   Click to Show/Hide
In Vitro Model Gastric adenocarcinoma SNU-16 cells CVCL_0076
References
Ref 1 Antibody drug conjugates.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.